Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
JAMA|September 20, 1985
Triad of markers for identifying children at high risk of developing insulin-dependent diabetes mellitusF Ginsberg-Fellner, M E Witt, B H Franklin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2003
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancerJ L Oh, E E Vokes, M S Kies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2001
Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancerC A Mantz, E E Vokes, M S Kies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2008
Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinomaB R Knab, J K Salama, A Solanki, et al.
Reviews of Infectious Diseases|March 1, 1985
Diabetes mellitus and autoimmunity in patients with the congenital rubella syndromeF Ginsberg-Fellner, M E Witt, B Fedun, et al.
Oral Oncology|October 30, 2012
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinomaD W Golden, S Rudra, M E Witt, et al.
Cancer Journal (Sudbury, Mass.)|April 28, 2001
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancerC A Mantz, E E Vokes, K Stenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancerD J Haraf, M Kies, A W Rademaker, et al.
Diabetologia|July 1, 1984
Congenital rubella syndrome as a model for type 1 (insulin-dependent) diabetes mellitus: increased prevalence of islet cell surface antibodiesF Ginsberg-Fellner, M E Witt, S Yagihashi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2011
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancersJ K Salama, D J Haraf, K M Stenson, et al.
Pageof 3